Lexicon Pharmaceuticals Statistics
Total Valuation
LXRX has a market cap or net worth of $996.70 million. The enterprise value is $865.33 million.
| Market Cap | 996.70M |
| Enterprise Value | 865.33M |
Important Dates
The last earnings date was Thursday, August 6, 2026, before market open.
| Earnings Date | Aug 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
LXRX has 444.96 million shares outstanding. The number of shares has increased by 7.98% in one year.
| Current Share Class | 444.96M |
| Shares Outstanding | 444.96M |
| Shares Change (YoY) | +7.98% |
| Shares Change (QoQ) | +9.35% |
| Owned by Insiders (%) | 1.46% |
| Owned by Institutions (%) | 34.24% |
| Float | 218.99M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 24.03 |
| Forward PS | 74.95 |
| PB Ratio | 5.71 |
| P/TBV Ratio | 7.67 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 20.87 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 13.37, with a Debt / Equity ratio of 0.34.
| Current Ratio | 13.37 |
| Quick Ratio | 13.07 |
| Debt / Equity | 0.34 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -6.50 |
Financial Efficiency
Return on equity (ROE) is -40.21% and return on invested capital (ROIC) is -16.04%.
| Return on Equity (ROE) | -40.21% |
| Return on Assets (ROA) | -14.32% |
| Return on Invested Capital (ROIC) | -16.04% |
| Return on Capital Employed (ROCE) | -23.16% |
| Weighted Average Cost of Capital (WACC) | 9.97% |
| Revenue Per Employee | $511,963 |
| Profits Per Employee | -$754,519 |
| Employee Count | 81 |
| Asset Turnover | 0.17 |
| Inventory Turnover | 8.50 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +107.41% in the last 52 weeks. The beta is 1.03, so LXRX's price volatility has been similar to the market average.
| Beta (5Y) | 1.03 |
| 52-Week Price Change | +107.41% |
| 50-Day Moving Average | 2.33 |
| 200-Day Moving Average | 1.79 |
| Relative Strength Index (RSI) | 45.67 |
| Average Volume (20 Days) | 2,551,968 |
Short Selling Information
The latest short interest is 32.75 million, so 7.36% of the outstanding shares have been sold short.
| Short Interest | 32.75M |
| Short Previous Month | 32.83M |
| Short % of Shares Out | 7.36% |
| Short % of Float | 14.96% |
| Short Ratio (days to cover) | 11.53 |
Income Statement
In the last 12 months, LXRX had revenue of $41.47 million and -$61.12 million in losses. Loss per share was -$0.16.
| Revenue | 41.47M |
| Gross Profit | 35.67M |
| Operating Income | -54.50M |
| Pretax Income | -61.12M |
| Net Income | -61.12M |
| EBITDA | -54.02M |
| EBIT | -54.50M |
| Loss Per Share | -$0.16 |
Balance Sheet
The company has $190.61 million in cash and $59.24 million in debt, with a net cash position of $131.37 million or $0.30 per share.
| Cash & Cash Equivalents | 190.61M |
| Total Debt | 59.24M |
| Net Cash | 131.37M |
| Net Cash Per Share | $0.30 |
| Equity (Book Value) | 174.53M |
| Book Value Per Share | 0.39 |
| Working Capital | 181.87M |
Cash Flow
| Operating Cash Flow | -64.99M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 481,000 |
| Net Borrowing | -7.26M |
| Free Cash Flow | -64.99M |
| FCF Per Share | -$0.15 |
Margins
Gross margin is 86.02%, with operating and profit margins of -131.43% and -147.38%.
| Gross Margin | 86.02% |
| Operating Margin | -131.43% |
| Pretax Margin | -147.38% |
| Profit Margin | -147.38% |
| EBITDA Margin | -130.27% |
| EBIT Margin | -131.43% |
| FCF Margin | n/a |
Dividends & Yields
LXRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -7.98% |
| Shareholder Yield | -7.98% |
| Earnings Yield | -6.13% |
| FCF Yield | -6.52% |
Analyst Forecast
The average price target for LXRX is $3.86, which is 72.32% higher than the current price. The consensus rating is "Buy".
| Price Target | $3.86 |
| Price Target Difference | 72.32% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | 15.08% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on May 21, 2015. It was a reverse split with a ratio of 1:7.
| Last Split Date | May 21, 2015 |
| Split Type | Reverse |
| Split Ratio | 1:7 |
Scores
LXRX has an Altman Z-Score of -6.5 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -6.5 |
| Piotroski F-Score | 2 |